{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:41:10Z","timestamp":1778636470313,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.urology.2005.03.080","type":"journal-article","created":{"date-parts":[[2005,6,5]],"date-time":"2005-06-05T07:14:55Z","timestamp":1117955695000},"page":"2-7","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S","title":["The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer"],"prefix":"10.1016","volume":"65","author":[{"given":"William R.","family":"Berry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.03.080_bib1","unstructured":"American Cancer Society Cancer facts and figures 2005. American Cancer Society Web site. Available at: http:\/\/www.cancer.org\/downloads\/STT\/CAFF\/CAFF2005f4PWSecured.pdf. Accessed May 10, 2005."},{"key":"10.1016\/j.urology.2005.03.080_bib2","unstructured":"SEER cancer statistics review, 1973\u20131999. Surveillance, Epidemiology and End Results (SEER) Web site. Available at: http:\/\/seer.cancer.gov\/csr\/1973_1999\/prostate.pdf. Accessed November 18, 2004"},{"key":"10.1016\/j.urology.2005.03.080_bib3","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2005.03.080_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2005.03.080_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1985.3.6.827","article-title":"A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma","volume":"3","author":"Eisenberger","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib7","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1023\/A:1008394823889","article-title":"Chemotherapy in advanced androgen-independent prostate cancer 1990\u20131999","volume":"11","author":"Culine","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib9","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib10","first-page":"314a","article-title":"A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC)","volume":"18","author":"Picus","year":"1999","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.urology.2005.03.080_bib11","first-page":"19","article-title":"A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer","volume":"26","author":"Friedland","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.urology.2005.03.080_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate","volume":"28","author":"Berry","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urology.2005.03.080_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000078328","article-title":"A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer","volume":"66","author":"Ferrero","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.urology.2005.03.080_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.11687","article-title":"Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma","volume":"98","author":"Gravis","year":"2003","journal-title":"Cancer"},{"issue":"suppl 6A","key":"10.1016\/j.urology.2005.03.080_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2005.01.067","article-title":"Future directions in the treatment of androgen-independent prostate cancer","volume":"65","author":"Petrylak","year":"2005","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505004309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505004309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T02:08:00Z","timestamp":1550887680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505004309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0090429505004309"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.03.080","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}